术中肝素使用与钝性主动脉损伤TEVAR术后死亡率降低相关且不增加出血并发症
基于Vascular Quality Initiative注册数据(2013-2019年),纳入655例因钝性主动脉损伤行TEVAR的患者,分析术中肝素使用与住院死亡率及出血并发症的关系。结果显示肝素使用与住院死亡率降低独立相关(OR 0.31,95%CI 0.11-0.86),且未增加输血或血肿风险;在III级损伤中,未使用肝素与下肢栓塞事件风险增加相关。
要点
- 术中肝素使用与BTAI患者TEVAR术后住院死亡率降低独立相关。
- 肝素使用未增加术中或术后输血需求及血肿形成风险。
- III级BTAI中,未使用肝素与下肢栓塞事件风险增加相关。
核心结论
- 术中肝素使用与BTAI患者TEVAR术后住院死亡率降低相关,且不增加出血并发症。
- 在无特定禁忌证时,TEVAR治疗BTAI应给予肝素。
研究设计与样本
- 回顾性队列研究,查询Vascular Quality Initiative注册数据库2013-2019年数据。
- 纳入655例因BTAI行TEVAR的患者,比较术中肝素使用与未使用者的结局。
- 采用单变量分析及多变量logistic回归评估肝素与住院死亡率的关联。
主要发现
- 肝素组住院死亡率5.1%,未使用肝素组12.9%(P < .01)。
- 肝素组ISS≥15比例70.2% vs 90.5%,严重头颈伤39.6% vs 62.9%(P < .0001)。
- III级BTAI中,未使用肝素者下肢栓塞事件发生率7.4% vs 1.8%(P < .05)。
- 多变量分析:肝素使用OR 0.31(95%CI 0.11-0.86,P < .05),女性OR 0.11(95%CI 0.11-0.86,P < .05)与生存改善相关。
- 年龄增加OR 1.06(95%CI 1.03-1.1,P < .001)、术后输血OR 1.06(95%CI 1.02-1.11,P < .01)、较高ISS OR 1.04(95%CI 1.01-1.07,P < .05)、术后心律失常OR 4.48(95%CI 1.10-18.18,P < .05)、术后卒中/TIA OR 5.54(95%CI 1.11-27.67,P < .05)与住院死亡率增加相关。
临床怎么用
- 对于无特定禁忌证的BTAI患者,TEVAR术中应考虑使用肝素。
- 肝素使用不增加出血风险,即使在高ISS或严重头颈伤患者中亦然。
- III级BTAI患者使用肝素可能降低下肢栓塞事件风险。
局限性
- 回顾性注册研究设计,存在选择偏倚可能。
- 肝素使用组伤情较轻(ISS≥15比例更低),混杂因素可能影响结果。
- 未报告肝素剂量及给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is an effective treatment of blunt thoracic aortic injury (BTAI). However, the risks and benefits of administering intraoperative heparin in trauma patients are not well-defined, especially with regard to bleeding complications. METHODS: The Vascular Quality Initiative registry was queried from 2013 to 2019 to identify patients who had undergone TEVAR for BTAI with or without the administration of intraoperative heparin. Univariate analyses were performed with the Student t test, Fisher exact test, or χ2 test, as appropriate. Multivariable logistic regression was then performed to assess the association of heparin with inpatient mortality. RESULTS: A total of 655 patients were included, of whom most had presented with grade III (53.3%) or IV (20%) BTAI. Patients receiving heparin were less likely to have an injury severity score (ISS) of ≥15 (70.2% vs 90.5%; P < .0001) or major head or neck injury (39.6% vs 62.9%; P < .0001). Patients receiving heparin also had a lower incidence of inpatient death (5.1% vs 12.9%; P < .01). Across all injury grades, heparin use was not associated with the need for intraoperative transfusion or postoperative transfusion or the development of hematoma. In patients with grade III BTAI, the nonuse of heparin was associated with an increased risk of lower extremity embolization events (7.4% vs 1.8%; P < .05). On multivariable logistic regression analysis for inpatient mortality, intraoperative heparin use (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.11-0.86; P < .05) and female gender (OR, 0.11; 95% CI, 0.11-0.86; P < .05) were associated with better survival, even after controlling for head and neck trauma and injury grade. In contrast, increased age (OR, 1.06; 95% CI, 1.03-1.1; P < .001), postoperative transfusion (OR, 1.06; 95% CI, 1.02-1.11; P < .01), higher ISS (OR, 1.04; 95% CI, 1.01-1.07; P < .05), postoperative dysrhythmia (OR, 4.48; 95% CI, 1.10-18.18; P < .05), and postoperative stroke or transient ischemic attack (OR, 5.54; 95% CI, 1.11-27.67; P < .05) were associated with increased odds of inpatient mortality. CONCLUSIONS: Intraoperative heparin use was associated with reduced inpatient mortality for patients undergoing TEVAR for BTAI, including those with major head or neck trauma and high ISSs. Heparin use did not increase the risk of hemorrhagic complications across all injury grades. Also, in patients with grade III BTAI, heparin use was associated with a reduced risk of lower extremity embolic events. Heparin appears to be safe during TEVAR for BTAI and should be administered when no specific contraindication exists.
引用
- Ho VT, George EL, Rothenberg KA, et al. Intraoperative heparin use is associated with reduced mortality without increasing hemorrhagic complications after thoracic endovascular aortic repair for blunt aortic injury. J Vasc Surg. 2020. PMID: 33348003. doi:10.1016/j.jvs.2020.12.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。